Crossmark Global Holdings, Inc. Krystal Biotech, Inc. Transaction History
Crossmark Global Holdings, Inc.
- $6.02 Billion
- Q2 2025
A detailed history of Crossmark Global Holdings, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 2,457 shares of KRYS stock, worth $481,473. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,457
Previous 2,370
3.67%
Holding current value
$481,473
Previous $427,000
21.08%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding KRYS
# of Institutions
317Shares Held
24.7MCall Options Held
418KPut Options Held
485K-
Black Rock Inc. New York, NY3.95MShares$774 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$553 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.66MShares$521 Million6.67% of portfolio
-
State Street Corp Boston, MA1.36MShares$266 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA942KShares$185 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $5.03B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...